The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Construction will begin this year with the new capacity anticipated by 2025
One thousand times more soluble than L-cystine at neutral pH
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Subscribe To Our Newsletter & Stay Updated
